{
    "url_original": "https://www.wsj.com/articles/drug-pricing-debate-in-washington-is-a-headache-for-pharma-11655463602?mod=markets_major_pos1",
    "url": "drug-pricing-debate-in-washington-is-a-headache-for-pharma-11655463602",
    "title": "Drug Pricing Debate in Washington Is a Headache for Pharma",
    "sub_head": "Last-ditch effort by Democrats to pass slimmed-down version of Build Back Better could include measures on drug pricing",
    "category_1": "Markets",
    "category_2": "Heard on the Street",
    "image_1_url": "https://images.wsj.net/im-565067?width=860&height=573",
    "image_1": "im-565067.jpg",
    "time": "2022-06-17 07:00:00",
    "body": "Big Pharma loves political gridlock. In fact, shares of pharmaceutical and biotechnology companies tend to outperform the broader market when Congress is divided.<br />With Republicans poised to flip control of the House in the midterm elections and President Biden’s “Build Back Better”—which included drug pricing reform—on life support, it seemed Big Pharma would soon be in the clear on tough action coming out of Washington."
}